Laboratory monitoring of the non-vitamin K oral anticoagulants.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018
   Trial
2. Prothrombin Time-International Normalized Ratio Predicts the Outcome of Atrial Fibrillation Patients Taking Rivaroxaban.Biomedicines · 2022
   Article
3. Direct oral anticoagulants: a review of common medication errors.Journal of thrombosis and thrombolysis · 2019
   Review
4. Drug Adherence in Patients With Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey: NOAC-TR.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018
   Article
5. Evaluation of the Antithrombotic Effects of Rivaroxaban and Apixaban Using the Total Thrombus-Formation Analysis SystemJournal of clinical medicine research · 2016
   Article
6. Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era.Vascular health and risk management · 2016
   Review
7. Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands.International journal of clinical pharmacy · 2015
   Observational
8. Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review.Clinical cardiology · 2015
   Review
9. Anticoagulation in Atrial Fibrillation - Current Concepts.Arrhythmia & electrophysiology review · 2015
   Article
10. Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants.Arrhythmia & electrophysiology review · 2015
    Article
11. Novel Oral Anticoagulants (NOACs) Roundtable - Hot Topics and Current Issues in association withArrhythmia & electrophysiology review · 2015
    Review

Corrections and comments

• Comment on
  Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as